Evidence map›Paper›PMID 40679331›Full record

ArticleTranslational vision science & technology2025

Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.

S Robert Levine, Dorene S Markel, Martin G Myers, Ryan Barunas, Jennifer K Sun, Dolly S Chang, Maureen G Maguire, Stela Vujosevic, Patrice E Fort, Mark Atkinson and 24 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

S Robert LevineMary Tyler Moore Vision Initiative, Greenwich, CT, USA.
Dorene S MarkelMary Tyler Moore Vision Initiative and Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI, USA.
Martin G MyersCaswell Diabetes Institute, University of Michigan, Ann Arbor, MI, USA.
Ryan BarunasJDRF Northeast Ohio & Michigan Chapter, Southfield, MI, USA.
Jennifer K SunJoslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
Dolly S ChangKodiak Sciences, Palo Alto, CA, USA.
Maureen G MaguireUniversity of Pennsylvania, Philadelphia, PA, USA.
Stela VujosevicEye Clinic, IRCCS MultiMedica, Milan, Italy.
Patrice E FortDepartment of Ophthalmology & Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Mark AtkinsonDepartment of Pathology and Diabetes Research Institute, University of Florida, Gainesville, FL, USA.
Fabio BaschieraBayer Pharmaceuticals, Basel, Switzerland.
Chris GatesBioinformatics Core, University of Michigan, Ann Arbor, MI, USA.
Judy M HuntLay Advisor MTM Vision, Villanova, PA, USA.
George L KingJoslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
Matthias KretzlerDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Phillip LaiPerfuse Therapeutics, San Francisco, CA, USA.
Drew LewisEstenda Solutions, Wayne, PA, USA.
Ulrich F O LuhmannRoche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Innovation Center, Basel, Switzerland.
Stephen McLeodAmerican Academy of Ophthalmology, San Francisco, CA, USA.
Carol OxenreiterLay Advisor, MTM Vision, Hilton Head, SC, USA.
Shelby UnsworthFast Forward Medical Innovation, University of Michigan Medical School, Ann Arbor, MI, USA.
Wiley ChambersFood and Drug Administration, Silver Spring, MD, USA.
Lloyd Paul AielloJoslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
Jason EhrlichOllin Biosciences, Austin, TX, USA.
Chris L GermanMyriad Genetics, Salt Lake City, UT, USA.
Ramin TadayoniUniversité Paris Cité, Lariboisière Hospital, Paris, France.
Risa M WolfDivision of Endocrinology and Diabetes, Department of Pediatrics, Johns Hopkins University Hospital, Baltimore, MD, USA.
Paolo SilvaJoslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
Eric CarlsonThe Carlson Company, Los Angeles, CA, USA.
Brian GottEntertainment Industry Foundation, Los Angeles, CA, USA.
Monica OxenreiterClose Concerns, San Francisco, CA, USA.
Nicole SextonEntertainment Industry Foundation, Los Angeles, CA, USA.
Arup DasDepartment of Ophthalmology, University of New Mexico Medical School, Albuequerque, NM, USA.
Thomas W GardnerDepartment of Ophthalmology & Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

The Mary Tyler Moore Vision Initiative (MTM Vision) Diabetic Retinal Disease (DRD) Clinical Endpoints Workshop was held on November 14, 2023. More than 130 clinicians, scientists, and representatives from funding and regulatory agencies, diagnostic, therapeutic, and biotech industry and patient advocates discussed the needs for new diagnostic and therapeutic approaches to preserve and restore retinal neurovascular unit integrity in people with diabetes. MTM Vision projects, notably updating the DRD staging system and severity scale, establishing a human ocular biorepository and resource, and validating useful clinical endpoints and biomarkers to accelerate development of new drugs and improve patient care were emphasized. A public-private consortium is essential to fulfill the objectives of MTM Vision for the benefit of persons with diabetes.

Indexed as

Diabetic RetinopathyHumans

Identifiers

PMID40679331
PMCPMC12302037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.